資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/27597
|
| 標題: | Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation |
| 作者: | Lin, Ching-Yih
Tian, Yu-Feng
Wu, Li-Ching
Chen, Li-Tzong
Lin, Li-Ching
Hsing, Chung-Hsi
Lee, Sung-Wei
Sheu, Ming-Jen
Lee, Hao-Hsien
Wang, Yu-Hui
Shiue, Yow-Ling
Wu, Wen-Ren
Huang, Hsuan-Ying
Hsu, Han-Ping
Li, Chien-Feng
Chen, Shang-Hung
Chen, Li-Tzong� |
| 貢獻者: | 保健營養系 |
| 關鍵字: | Chromatin Remodeling Factor
Preoperative Radiotherapy
Sphincter Preservation
Functional-Analysis
Tumor Response
Acute Toxicity
Dna-Damage
Carcinoma
Overexpression
Survival |
| 日期: | 2012-08 |
| 上傳時間: | 2014-03-21 16:14:44 (UTC+8) |
| 出版者: | Bmj Publishing Group |
| 摘要: | Aims Neoadjuvant chemoradiation therapy (CRT) is an increasingly used therapeutic strategy for rectal cancer. Clinically, it remains a major challenge to predict therapeutic response and patient outcome after CRT. Rsf-1 (HBXAP), a novel nuclear protein with histone chaperon function, mediates ATPase-dependent chromatin remodelling and confers tumour aggressiveness and predicts therapeutic response in certain carcinomas. However, the expression of Rsf-1 has never been reported in rectal cancer. This study examined the predictive and prognostic impacts of Rsf-1 expression in patients with rectal cancer following neoadjuvant CRT.Methods Rsf-1 immunoexpression was retrospectively assessed for pre-treatment biopsies of 172 rectal cancer patients without initial distant metastasis. All of them were treated with neoadjuvant CRT followed by surgery. The results were correlated with the clinicopathological features, therapeutic response, tumour regression grade and metastasis-free survival (MeFS), local recurrent-free survival and disease-specific survival.Results Present in 82 cases (47.7%), high-expression of Rsf-1 was associated with advanced pre-treatment tumour status (T3, T4, p=0.020), advanced post-treatment tumour status (T3, T4, p<0.001) and inferior tumour regression grade (p=0.028). Of note, high-expression of Rsf-1 emerged as an adverse prognosticator for diseases-specific survival (p=0.0092) and significantly predicted worse MeFS (p=0.0006). Moreover, high-expression of Rsf-1 also remained prognostic independent for worse MeFS (HR 2.834; p=0.0214).Conclusions High-expression of Rsf-1 is associated with poor therapeutic response and adverse outcome in rectal cancer patients treated with neoadjuvant CRT, which confers tumour aggressiveness and therapeutic resistance through chromatin remodelling and represents a potential prognostic biomarker in rectal cancer. |
| 關聯: | Journal of Clinical Pathology, 65(8), 687-692 |
| 顯示於類別: | [保健營養系(所) ] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 1920 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
